People with HIV not on antiretroviral treatment were 45% more likely to die after admission to hospital with COVID-19 compared to people taking antiretroviral treatment, a large study of in-hospital deaths from COVID-19 in South Africa has concluded. The study also found an increased risk of death in people with HIV with CD4 counts below… Read More »
Long-acting cabotegravir (Vocabria) and rilpivirine (Rekambys) injections maintain viral suppression for two years, according to follow-up study results presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI). The European Medicines Agency (EMA) approved the injectable combination — the first complete HIV regimen that does not require daily pills — in December 2020.… Read More »
Dolutegravir-based antiretroviral treatment (ART) in combination with an NRTI backbone will not be effective in Togo, due to high levels of resistance to the NRTI class of drugs, according to a study presented by Professor Mounerou Salou of the Laboratoire Biolim in Togo at the recent 20th International Conference on AIDS and STIs in Africa (ICASA)… Read More »